The relationship between price regulation and pharmaceutical profit margins

Applied Economics Letters

Volumn 10, Issue 8, 2003, Pages 467-470

  Vernon, John A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BALDWIN WALLACE COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHARMACEUTICAL INDUSTRY; PRICE DYNAMICS; PROFITABILITY; REGULATORY APPROACH;

EID: 0041814558     PISSN: 13504851     EISSN: None     Source Type: Journal    
DOI: 10.1080/1350485032000090776     Document Type: Article

References (9)

1. Berndt, E. R. (2000) International comparisons of pharmaceutical prices: what do we know, and what does it mean? Journal of Health Economics, 19(2), 283-87.
2. Danzon, P. M. (2000) Making sense of drug prices, Regulation, 23(1), 56-63.
3. Fisher, F. M. (1987) On the misuse of the profit-sales ratio to infer monopoly power, Rand Journal of Economics, 18(3), 384-96.
4. Grabowski, H. G. and Vernon, J. M. (2000) The determinants of pharmaceutical research and development expenditures, Journal of Evolutionary Economics, 10, 201-15.
5. Hsiao, C. (1986) Analysis of Panel Data, Cambridge University Press, Cambridge.
6. Lichtenberg, F. R. (2001) Probing the link between gross profitability and R&D spending, Health Affairs, 20, 221-22.
7. Scherer, F. M. (2001) The link between gross profitability and pharmaceutical R&D spending, Health Affairs, 20, 216-20.
8. Scrip Publications Pharmaceutical Company League Tables and Year Books 1994-1999. PJB Publications Ltd, London, England.
9. Vernon, J. A. (2003) Drug Research and Price Controls, Regulation, 25, 4.